Soft tissue sarcomas (STSs) are a typical group that differs from one of the tumours with distinct histopathological subtypes. It is estimated in 21% of all malignant diseases in children, and less than 1% of all adult malignancies [1] Adjuvant radiation is well-established for the conservative treatment of soft tissue sarcomas. The National Cancer Comprehensive Cancer Network guidelines recommend that postoperative radiotherapy be administered to most patients with sarcomas of the soft tissues of the extremities and upper extremity. When only low-dose (LDR) brachytherapy (BT) is used, 45-Gy doses are used in patients with severe oedema. In cases where margins are positive, a combination of 50 Gy beam radiotherapy (EBRT) and 16-20 Gy of LDR brachytherapy or equivalent high-dose rate (HDR) is warranted. This range of radiation concentrations produces a five-year cell control rate of 75-90% [3 - 14]. LDR brachytherapy has been a frequently used method [15 - 23], and reports of high-dose (HDR) brachytherapy are very small in number [24 - 27]. However, HDR brachytherapy is widely used due to better compliance with radiation safety policies, more complex radiation planning and the possibility of outpatient treatment.